Silencing ZIC2 abrogates tumorigenesis and anoikis resistance of non-small cell lung cancer cells by inhibiting Src/FAK signaling

MLA

Aibin Liu, et al. “Silencing ZIC2 Abrogates Tumorigenesis and Anoikis Resistance of Non-Small Cell Lung Cancer Cells by Inhibiting Src/FAK Signaling.” Molecular Therapy: Oncolytics, vol. 22, no. 195–208, Sept. 2021, pp. 195–208. EBSCOhost, https://doi.org/10.1016/j.omto.2021.05.008.

APA

Aibin Liu, Huayan Xie, Ronggang Li, Liangliang Ren, Baishuang Yang, Longxia Dai, Wenjie Lu, Baoyi Liu, Dong Ren, Xin Zhang, Qiong Chen, Yanming Huang, & Ke Shi. (2021). Silencing ZIC2 abrogates tumorigenesis and anoikis resistance of non-small cell lung cancer cells by inhibiting Src/FAK signaling. Molecular Therapy: Oncolytics, 22(195–208), 195–208. https://doi.org/10.1016/j.omto.2021.05.008

Chicago

Aibin Liu, Huayan Xie, Ronggang Li, Liangliang Ren, Baishuang Yang, Longxia Dai, Wenjie Lu, et al. 2021. “Silencing ZIC2 Abrogates Tumorigenesis and Anoikis Resistance of Non-Small Cell Lung Cancer Cells by Inhibiting Src/FAK Signaling.” Molecular Therapy: Oncolytics 22 (195–208): 195–208. doi:10.1016/j.omto.2021.05.008.